Subject: Re: Fwd: Gilead Georgia Backgrounder
From: nino mamaladze <[email-masked]>
To: Sonia Choi <[email-masked]>
Date: Mon, 20 Apr 2015 20:31:20 +0000

Thank you Sonia, 

This information will be taken into consideration for tomorrow event.

Yours faithfully, 
Nino

-----Original Message-----
From: Sonia Choi <[email-masked]>
To: nino mamaladze <[email-masked]>
Date: Mon, 20 Apr 2015 19:47:53 +0100
Subject: Fwd: Gilead Georgia Backgrounder

> Dear Nino - attached is the updated press release to which I referred
> in my previous email.
> 
> Many thanks,
> Sonia
> 
> Begin forwarded message:
> 
> From: Sonia Choi <[email-masked]<mailto:[email-masked]>>
> Date: April 19, 2015 at 9:42:41 PM GMT+4
> To: "Averhoff, Francisco (CDC/OID/NCHHSTP)"
> <[email-masked]<mailto:[email-masked]>>, Graeme Robertson
> <[email-masked]<mailto:[email-masked]>>,
> "Morgan, Juliette (CDC/CGH/DGHP)" <[email-masked]<mailto:[email-masked]>>,
> "[email-masked]<mailto:[email-masked]>'"
> <[email-masked]<mailto:[email-masked]>>,
> "[email-masked]<mailto:[email-masked]>'"
> <[email-masked]<mailto:[email-masked]>>,
> "[email-masked]<mailto:[email-masked]>'"
> <[email-masked]<mailto:[email-masked]>>
> Cc: Enrico Magnanelli
> <[email-masked]<mailto:[email-masked]>>,
> Gregg Alton <[email-masked]<mailto:[email-masked]>>
> Subject: RE: Gilead Georgia Backgrounder
> 
> Thank you, Francisco.
> 
> Dear Minister – please find attached an updated draft press release
> for your consideration that incorporates Francisco’s suggested
> changes. The main changes were the inclusion of detail on phases 1 and
> 2 and the addition of a quote from John Ward.
> 
> Best wishes,
> Sonia
> 
> 
> From: Averhoff, Francisco (CDC/OID/NCHHSTP) [mailto:[email-masked]]
> Sent: 19 April 2015 12:03
> To: Sonia Choi; Graeme Robertson; Morgan, Juliette (CDC/CGH/DGHP);
> [email-masked]<mailto:[email-masked]>';
> [email-masked]<mailto:[email-masked]>';
> [email-masked]<mailto:[email-masked]>'
> Cc: Enrico Magnanelli
> Subject: Re: Gilead Georgia Backgrounder
> 
> Dear Sonia,
> 
> 
> I think it is necessary to emphasize from original TPs that this Phase
> I is a compassionate use/early intervention targeting those with more
> advanced liver disease, at risk of morbidity/mortality, as part of
> greater elimination program. I will send suggested revisions. Thx, FA
> 
> From: Sonia Choi [mailto:[email-masked]]
> Sent: Friday, April 17, 2015 10:37 PM
> To: Graeme Robertson
> <[email-masked]<mailto:[email-masked]>>;
> Morgan, Juliette (CDC/CGH/DGHP); Averhoff, Francisco (CDC/OID/NCHHSTP);
> David Sergeenko <[email-masked]<mailto:[email-masked]>>;
> David Chitaia <[email-masked]<mailto:[email-masked]>>; valeri
> ([email-masked]<mailto:[email-masked]>)
> <[email-masked]<mailto:[email-masked]>>
> Cc: Enrico Magnanelli
> <[email-masked]<mailto:[email-masked]>>
> Subject: RE: Gilead Georgia Backgrounder
> 
> Dear all –
> 
> Attached please find the latest draft press release. We have included a
> quote from Gilead and there is a placeholder for a quote from CDC.
> 
> Many thanks,
> Sonia
> 
> From: Graeme Robertson
> Sent: 17 April 2015 20:06
> To: Morgan, Juliette (CDC/CGH/DGHP); Averhoff, Francisco
> (CDC/OID/NCHHSTP); David Sergeenko; David Chitaia; valeri
> ([email-masked]<mailto:[email-masked]>)
> Cc: Sonia Choi; Enrico Magnanelli
> Subject: Gilead Georgia Backgrounder
> 
> Dear All,
> 
> Please see attached backgrounder that we have developed utilising what
> Francisco had provided.
> 
> Best wishes
> 
> Graeme
> 
> Graeme Robertson
> Director
> Access Operations & Emerging Markets
> DISCLAIMER If you have received this message in error, please contact
> the sender immediately by return e-mail and notify the sender and then
> delete this message (including any attachments) from your system. This
> communication and any attachments contain information which is
> confidential and may also be legally privileged. It is for the
> exclusive use of the intended recipient(s). If you are not the intended
> recipient(s) please note that any form of disclosure, distribution,
> copying or use of this communication or the information in it or in any
> attachments is strictly prohibited and may be unlawful. E-mail
> communications cannot be guaranteed to be secure or error free, as
> information could be intercepted, corrupted, amended, lost, destroyed,
> arrive late or incomplete, or contain viruses. Gilead does not accept
> liability for any such matters or their consequences. Anyone who
> communicates with Gilead by e-mail is taken to accept the risks in
> doing so. Gilead has taken every reasonable precaution to ensure that
> any attachment to this e-mail has been swept for viruses. However,
> Gilead cannot accept liability for any damage sustained as a result of
> viruses and would advise that you carry out your own virus checks
> before opening any attachment. Gilead Sciences Europe Ltd ; Registered
> as a limited company in England and Wales ; Registered number 5510315
> Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park
> ; Uxbridge ; UB11 1AF ; England